As the pharmaceutical industry advances toward low global warming potential (GWP) propellants like HFA152a and HFO1234ze(E), understanding material compatibility becomes critical, especially when it comes to leachables from common device components.
In a recent evaluation, a group of pulmonary experts at Kindeva assessed the extractable levels associated with various polybutylene terephthalate (PBT) suppliers in pressurized metered dose inhaler (pMDI) formulations containing ethanol and low-GWP propellants. The study was designed to simulate worst-case conditions and generate actionable insights for development teams reformulating with emerging propellant systems.
The findings reinforce the importance of careful material selection and formulation control during the transition to sustainable pMDI technologies:
- Propellant choice affects extractable levels
- Increasing ethanol concentration increases leachables
- PBT grade influences extractable output
- Oligomer presence may impact performance
Understanding the interactions between propellant, co-solvent and material grade is essential for ensuring product stability, safety and compliance as low-GWP formulations progress toward commercialization.
Curious about the full impact of propellant, ethanol and material selection on leachables? Explore the full poster presentation.
Connect with Kindeva to discover how our end-to-end expertise helps future-proof your low-GWP inhalation products by mitigating extractables risk and accelerating sustainable pMDI development.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
The impact of inlet design on HFA-152a pMDI drug delivery
When assessing aerodynamic particle size distribution (APSD) using the Next Generation Impactor (NGI), throat model selection can significantly influence drug deposition outcomes. Accurate deposition data is essential for optimising pMDI design and ensuring consistent, effective drug delivery to patients. Recent research by our pulmonary/pMDI experts—Aaron Taylor, Chad Haraldson, and Stephen Stein at Kindeva—explores how United […]
Learn More
The three key trends that will most impact drug development in 2025
The speed of change in the drug development and manufacturing sector requires its stakeholders to be proactive in understanding and addressing key trends and directions the industry is taking. As a global market of considerable size and significance, the value of which is anticipated to grow from $589.06 billion in 2024 to $632.71 billion in […]
Learn More
Microneedle array patch characterization recording
Microneedle array patches (MAPs) have the potential to transform delivery of medications and vaccines. While this innovative drug delivery format could result in improved efficiency across a wide range of therapeutics, it also brings critical challenges. To successfully move from concept to commercialization, MAP manufacturers must consider scalability, regulatory compliance, and other complexities. In this […]
Learn More
Microneedle array patch characterization presentation
Microneedle array patches (MAPs) are a transformative innovation in drug delivery, with the potential to redefine how medications and vaccines reach patients. MAPs promise a simpler, more effective way to deliver a wide range of therapeutics, but their journey from concept to commercialization is filled with critical challenges. From scaling manufacturing to ensuring regulatory compliance, […]
Learn More
Addressing top tech transfer challenges
Technology transfer represents a critical bridge between development and commercial manufacturing. This complex process — moving product and process knowledge between development and manufacturing teams or between different manufacturing sites — demands precision at every stage. The implications of technology transfer extend beyond knowledge sharing. Each decision during this process directly impacts manufacturing efficiency, regulatory […]
Learn More
Tech transfer commercial manufacturing mindset
Technology transfer (tech transfer) moves product and process knowledge between teams or partners and acts as a crucial bridge between ideation and commercialization. Especially for complex products like sterile injectables, a smooth tech transfer process is essential. In this white paper, discover valuable strategies to embrace a commercial manufacturing mindset from day one. Download your […]
Learn More
HFA152a green propellant capabilities
With evolving regulations and a growing push for sustainability, switching pressurized metered-dose inhalers (pMDIs) to green propellants is becoming increasingly essential. One of the most promising low global warming potential (GWP) options is HFA152a. In this white paper, we share insights on transitioning to HFA152a. Download your copy to discover: An overview of sustainability regulations […]
Learn More
Sterile product introduction and tech transfers in a crowded market
The tech transfer landscape for sterile products is increasingly complex, with pressure to reduce time to market. Find out how to navigate common challenges and avoid costly delays or oversights in this presentation from our Director, Client Portfolio & Relationship Management, Kim Brown. Download your copy to explore: Benefits of a commercial manufacturing mindset How […]
Learn More
Eliminating the syringe with inhaled and microneedle vaccine delivery systems
Interest in inhaled and intradermal vaccine delivery systems isn’t just a modern innovation — one of history’s most effective vaccination campaigns also used mucosal or dermal delivery. In 1777, George Washington mandated smallpox inoculation for his troops using either arm scratches (intradermal) or nasal inhalation (mucosal), a strategy that proved crucial in the American victory.1 […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.